As of now, when it comes to protection against prevalent diseases, Dr Gagandeep Kang, a renowned virologist, points that our ...

The US Food and Drug Administration on Friday approved the first flu vaccine that does not have to be administered by a ...

FDA drug alerts in pulmonology, including drug approvals/warnings, vaccine approvals, medical device recalls/updates, and ...

Pneumococcal bacteria are present in the normal microbiome of the nose of many children and adults. In certain circumstances, ...

The U.S. vaccine policy landscape is broader and changing more rapidly than at any point in its modern history, and those ...

Shares in vaccine ... causes invasive pneumococcal disease, the company said. Vaxcyte’s shot covers an additional 11 strains than Prevnar 20, for a total of 31. The company plans to advance its ...

Pneumococcal vaccination may reduce the risk for pneumonia-related morbidity and mortality among patients with immune-mediated inflammatory diseases.

Public health authorities outline who needs which vaccines, organized by age and other key variables—important information ...

Following the summer break, the 2024 Formula 1 season resumes this weekend with the Dutch Grand Prix in Zandvoort. Max Verstappen holds a commanding 78-point lead at the top of the drivers ...

Background: Respiratory syncytial virus (RSV) vaccines could reduce disease burden and costs in older Canadian adults, but vaccination program cost-effectiveness is unknown. We evaluated the ...

Vaxcyte’s market potential is driven by $13.3B TAM in pneumococcal vaccine market, with potential FDA approval by late 2026 ...

The pneumococcal polysaccharide vaccine (PPV) is currently recommended for older adults and high-risk subjects, including patients with chronic obstructive pulmonary disease (COPD) and asthma.